Tricida IncChange company Symbol lookupSelect an option...TCDAQ Tricida IncHROWL HARROW HEALTH 8 625 SNR NTSMLTX MoonLake ImmunotherapeuticsTRTN Triton International LtdPAYA Paya Holdings IncMA Mastercard IncMWRK MetaWorks Platforms IncNSRGY Nestle SAMIN MFS? Intermediate Income FundMCO Moody's CorpGo
Tricida, Inc. is a pharmaceutical company, which is focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101). TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The Company's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.